Platelets and coronary artery disease

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100

[2] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961

[3] LOCALIZATION OF AN ARG-GLY-ASP RECOGNITION SITE WITHIN AN INTEGRIN ADHESION RECEPTOR [J]. SCIENCE, 1988, 242 (4875) : 91 - 93

[4] FUSTER V, 1992, NEW ENGL J MED, V326, P310

[5] A BETA-3 INTEGRIN MUTATION ABOLISHES LIGAND-BINDING AND ALTERS DIVALENT-CATION DEPENDENT CONFORMATION [J]. SCIENCE, 1990, 249 (4971) : 915 - 918

[6] TICLOPIDINE - A NEW ANTIPLATELET AGENT FOR THE SECONDARY PREVENTION OF STROKE [J]. CLINICAL NEUROPHARMACOLOGY, 1994, 17 (01) : 23 - 31

[7] SAVI P, 1994, THROMB HAEMOSTASIS, V72, P313

[8] HYPERCOAGULABLE STATES - MOLECULAR-GENETICS TO CLINICAL-PRACTICE [J]. LANCET, 1994, 344 (8939-4): : 1739 - 1742

[9] A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) : 1084 - 1089

[10] RANDOMIZED TRIAL OF CORONARY INTERVENTION WITH ANTIBODY AGAINST PLATELET IIB/IIIA INTEGRIN FOR REDUCTION OF CLINICAL RESTENOSIS - RESULTS AT 6 MONTHS [J]. LANCET, 1994, 343 (8902) : 881 - 886

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100

[2] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961

[3] LOCALIZATION OF AN ARG-GLY-ASP RECOGNITION SITE WITHIN AN INTEGRIN ADHESION RECEPTOR [J]. SCIENCE, 1988, 242 (4875) : 91 - 93

[4] FUSTER V, 1992, NEW ENGL J MED, V326, P310

[5] A BETA-3 INTEGRIN MUTATION ABOLISHES LIGAND-BINDING AND ALTERS DIVALENT-CATION DEPENDENT CONFORMATION [J]. SCIENCE, 1990, 249 (4971) : 915 - 918

[6] TICLOPIDINE - A NEW ANTIPLATELET AGENT FOR THE SECONDARY PREVENTION OF STROKE [J]. CLINICAL NEUROPHARMACOLOGY, 1994, 17 (01) : 23 - 31

[7] SAVI P, 1994, THROMB HAEMOSTASIS, V72, P313

[8] HYPERCOAGULABLE STATES - MOLECULAR-GENETICS TO CLINICAL-PRACTICE [J]. LANCET, 1994, 344 (8939-4): : 1739 - 1742

[9] A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) : 1084 - 1089

[10] RANDOMIZED TRIAL OF CORONARY INTERVENTION WITH ANTIBODY AGAINST PLATELET IIB/IIIA INTEGRIN FOR REDUCTION OF CLINICAL RESTENOSIS - RESULTS AT 6 MONTHS [J]. LANCET, 1994, 343 (8902) : 881 - 886